FREMONT, Calif., Aug. 22, 2018 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., a privately-held, clinical stage biotechnology company focused on biomarker-driven, small molecule therapeutics for patients with cancer, today announced presentations of preclinical data by its collaborator, the University of Auckland, from ongoing studies of Rain’s lead candidate, tarloxotinib, at the New Zealand Society for Oncology Conference being held August 24-25, 2018 and the Queenstown Molecular Biology Meeting being held August 27-29, 2018, both in Queenstown, NZ. The poster presentations describe the plasma membrane reductase responsible for the activation of tarloxotinib exclusively in hypoxic environments. This unique characteristic increases the specificity of tarloxotinib for cancer cells, making it an ideal candidate for the treatment of EGFR Exon 20 mutation-driven non-small cell lung cancer.
Details on the presentations by the University of Auckland’s Translational Therapeutics team are as follows:
New Zealand Society for Oncology Conference
Poster Presentation Title: Discovery of the plasma membrane reductase responsible for the activation of the cell-excluded hypoxia-activated prodrug Tarloxotinib
Presenter: Shevan Silva
Date/Time: August 24, 2018 at 4:45 p.m. NZST
Location: Queenstown Memorial Centre
Queenstown Molecular Biology Meeting
Poster Presentation Title: Discovery of the plasma membrane reductase responsible for the activation of the cell-excluded hypoxia-activated prodrug Tarloxotinib
Presenter: Shevan Silva
Date/Time: August 28, 2018 at 4:30 p.m. NZST
Location: Rydges Hotel, Queenstown
Additional details can be found on the New Zealand Society for Oncology website and the Queenstown Molecular Biology Meeting website. A copy of presentation materials can be accessed by visiting the Science and Publications section of the Rain website after the presentations conclude.
About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a privately-held biotechnology company developing biomarker-driven small molecule therapeutics for patients with cancer. Rain’s lead program, Tarloxotinib, is a hypoxia-activated prodrug of a potent pan-ErbB inhibitor in development as a treatment for non-small cell lung cancer patients with EGFR / ErbB Exon 20 insertion mutations. Rain Therapeutics Inc. has worldwide development and commercialization rights for Tarloxotinib through an exclusive license from the University of Auckland. For more information, visit www.rainthera.com
About the Translational Therapeutics Team, University of Auckland.
The Translational Therapeutics Team is a oncology research group lead by Associate Professors Adam Patterson and Jeff Smaill that specialize in all aspects of the design and development of hypoxia activated prodrugs. The team is based in the Auckland Cancer Society Research Centre, within the Faculty of Medical and Health Sciences, located at The University of Auckland. Funding support is primarily through the Health Research Council of New Zealand, the Maurice Wilkins Centre for Molecular Biodiversity and Cancer Society Auckland and Northland.
Media Contact
Cait Williamson, Ph.D.
LifeSci Public Relations
+1.949.290.4945
cait@lifescipublicrelations.com